132 related articles for article (PubMed ID: 3484714)
41. Comparison of the short-term effects of mepindolol and propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis.
Braillon A; Calès P; Lebrec D
Int J Clin Pharmacol Res; 1985; 5(4):223-8. PubMed ID: 4055165
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis.
Hillon P; Lebrec D; Muńoz C; Jungers M; Goldfarb G; Benhamou JP
Hepatology; 1982; 2(5):528-31. PubMed ID: 7118065
[TBL] [Abstract][Full Text] [Related]
43. Endoscopic demonstration that vasopressin but not propranolol produces gastric mucosal ischemia in dogs with portal hypertension.
Leung FW; Jensen DM; Guth PH
Gastrointest Endosc; 1988; 34(4):310-3. PubMed ID: 3261702
[TBL] [Abstract][Full Text] [Related]
44. The selective effects of dopamine and dobutamine on liver circulation in the dog.
Kinoshita G; Washizu M; Murata N; Kondo M; Matsukura Y; Washizu T; Motoyoshi S
J Vet Med Sci; 1995 Apr; 57(2):293-7. PubMed ID: 7492649
[TBL] [Abstract][Full Text] [Related]
45. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function.
Navasa M; Chesta J; Bosch J; Rodés J
Gastroenterology; 1989 Apr; 96(4):1110-8. PubMed ID: 2925055
[TBL] [Abstract][Full Text] [Related]
46. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group.
Conn HO; Grace ND; Bosch J; Groszmann RJ; Rodés J; Wright SC; Matloff DS; Garcia-Tsao G; Fisher RL; Navasa M
Hepatology; 1991 May; 13(5):902-12. PubMed ID: 2029994
[TBL] [Abstract][Full Text] [Related]
47. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage.
Groszmann RJ; Bosch J; Grace ND; Conn HO; Garcia-Tsao G; Navasa M; Alberts J; Rodes J; Fischer R; Bermann M
Gastroenterology; 1990 Nov; 99(5):1401-7. PubMed ID: 2210246
[TBL] [Abstract][Full Text] [Related]
48. Theoretical and practical considerations in the treatment of portal hypertension secondary to hepatic cirrhosis.
Bizer LS
Am Surg; 1984 Oct; 50(10):524-9. PubMed ID: 6385791
[TBL] [Abstract][Full Text] [Related]
49. Serotonin blockade in conscious, unrestrained cirrhotic dogs with portal hypertension.
Mastaï R; Rocheleau B; Huet PM
Hepatology; 1989 Feb; 9(2):265-8. PubMed ID: 2492251
[TBL] [Abstract][Full Text] [Related]
50. Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension.
Navasa M; Bosch J; Reichen J; Bru C; Mastai R; Zysset T; Silva G; Chesta J; Rodés J
Hepatology; 1988; 8(4):850-4. PubMed ID: 3391511
[TBL] [Abstract][Full Text] [Related]
51. Similarity of arterial and intravenous vasopressin on portal and systemic hemodynamics.
Barr JW; Lakin RC; Rösch J
Gastroenterology; 1975 Jul; 69(1):13-9. PubMed ID: 1150017
[TBL] [Abstract][Full Text] [Related]
52. Effects of tham, isoprenaline and propranolol on blood flow and vascular resistances of the liver after in- and outflow occlusion. Relation with the splanchnic shock.
Stoitchcov E; Kawai T; Bleser F; Benichoux R
Eur Surg Res; 1976; 8(3):211-26. PubMed ID: 947759
[TBL] [Abstract][Full Text] [Related]
53. Acute effect of propranolol on splanchnic circulation in normal and portal hypertensive rats.
Calès P; Braillon A; Girod C; Lebrec D
J Hepatol; 1985; 1(4):349-57. PubMed ID: 4056347
[TBL] [Abstract][Full Text] [Related]
54. [Per-rectal scintigraphy of the portal system with pertechnetate TC-99M: effect of propranolol on portosystemic collateral circulation in patients with cirrhosis. Part II].
Bołdys H; Hartleb M; Rudzki K; Nowak A; Nowak S
Pol Arch Med Wewn; 1994 Jul; 92(1):19-25. PubMed ID: 7971473
[TBL] [Abstract][Full Text] [Related]
55. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension.
Sarin SK; Groszmann RJ; Mosca PG; Rojkind M; Stadecker MJ; Bhatnagar R; Reuben A; Dayal Y
J Clin Invest; 1991 Mar; 87(3):1032-6. PubMed ID: 1900306
[TBL] [Abstract][Full Text] [Related]
56. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis.
Escorsell A; Feu F; Bordas JM; García-Pagán JC; Luca A; Bosch J; Rodés J
J Hepatol; 1996 Apr; 24(4):423-9. PubMed ID: 8738728
[TBL] [Abstract][Full Text] [Related]
57. Reduced splanchnic vasoconstriction to angiotensin II in conscious rats with biliary cirrhosis.
Braillon A; Cailmail S; Gaudin C; Lebrec D
J Hepatol; 1993 Jan; 17(1):86-90. PubMed ID: 8445224
[TBL] [Abstract][Full Text] [Related]
58. Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis.
Merkel C; Gatta A; Bolognesi M; Finucci G; Battaglia G; Angeli P; Zuin R
Dig Dis Sci; 1988 Sep; 33(9):1103-9. PubMed ID: 3409797
[TBL] [Abstract][Full Text] [Related]
59. Effect of propranolol on hepatic blood flow in patients with cirrhosis.
Braillon A; Jirón MI; Valla D; Calès P; Lebrec D
Clin Pharmacol Ther; 1985 Apr; 37(4):376-80. PubMed ID: 3978998
[TBL] [Abstract][Full Text] [Related]
60. Nipradilol, a new beta-blocker with vasodilatory properties, in experimental portal hypertension: a comparative haemodynamic study with propranolol.
Um S; Nishida O; Tokubayashi M; Kimura F; Kita T
J Gastroenterol Hepatol; 1993; 8(5):414-9. PubMed ID: 8105997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
